Satralizumab Continues to Display Long-Term Efficacy in AQP4-IgG-Seropositive NMOSD.

Published Date: 15 Oct 2023

The SAkuraMoon study's annual relapse rate was consistently low in patients receiving satralizumab, according to a recent analysis, and a sizable portion of patients did not experience mild relapses, severe relapses, or worsening disability.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Vaccine shows promise for pancreatic cancer, study finds

2.

After a plane crash, a surgeon dies; Austin is released from the hospital; and an animal pandemic spreads.

3.

FAPI PET/CT enhances the staging of recently discovered breast cancer, according to comparative analysis.

4.

"A lot" of aspirin reduces the risk of ovarian cancer, regardless of genetic factors, according to the JAMA study.

5.

Tumor characteristics found to differ for melanomas in children, teens and young adults


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot